Beta-Blockers May Enhance Immunotherapy for MelanomaMedscapeSpecifically, among 195 patients with metastatic melanoma who were treated with immunotherapy (interleukin-2, cytotoxic t-lymphocyte associated protein 4, and/or programmed cell death-1 agents… Continue reading
|
FDA roadmap highlights opioids, gene therapy, biosimilars
BioPharma Dive The Food and Drug Administration’s 2018 strategic policy roadmap highlights the battle against opioid addiction, the growth of cell and gene therapy, and using competition to improve access and make drugs more affordable. Identifying where pharma is … |
Immuno-Oncology News |
Certain Types of Gut Bacteria May Increase Immunotherapy’s Effectiveness in Treating Melanoma, Study Finds
Immuno-Oncology News Despite their proven therapeutic benefit, only about 35 percent of melanoma patients who receive immunotherapy see a significant benefit. University of Chicago researchers now have shown that this could be related to microorganisms naturally found in … |
|
CRISPR And Axovant: What The Market Thinks
Seeking Alpha Let’s go to the NASDAQ for some insight on a couple of recent biopharma stories. First off is Axovant (NASDAQ:AXON), a company that’s interesting in a number of distressing ways. I last wrote about them here, after their Alzheimer’s candidate came up … |
EurekAlert (press release) |
Stem Cell Transplant Improves Severe Scleroderma Survival
Specialty Pharmacy Times Findings from a clinical trial suggest that transplanting a patient’s own blood-forming stem cells may be beneficial for patients with severe scleroderma. This treatment was found to improve survival and quality of life for patients with this serious … Scleroderma study: Hope for a longer life for patients with rare autoimmune disorderEurekAlert (press release) |